Thymic Stromal Lymphopoietin (TSLP) in Vitiligo

Vitiligo Clinical Trial

Official title:

Study of the Cutaneous Expression of Thymic Stromal Lymphopoietin (TSLP) in a Sample of Vitiligo Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03367273
• Other study ID #: Dermatology 2
• Status: Completed
• Phase: N/A
• First received: December 5, 2017
• Last updated: December 18, 2017
• Start date: January 2017
• Est. completion date: July 2017

Study information

• Verified date: December 2017
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

study & verify the hypothesis of the involvement of TSLP in the pathogenesis of vitiligo in comparison to their levels in the healthy control persons.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: July 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• • Patients with generalized non-segmental vitiligo.

• Both sexes.

• Age < 18 years old age.

• New cases or cases not receiving any medication for at least 3 months ago.

Exclusion Criteria:

• • Age: Patients < 18 years.

• Segmental or universal vitiligo.

• Pregnant and lactating females. Autoimmune diseases

Related Conditions & MeSH terms

• Vitiligo

Intervention

Other:
• skin biopsy
Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression levels of TSLP in patients of Vitiligo.		7 months